Aspire Biopharma Holdings Overview
Aspire Biopharma Holdings (ASBP) has a ROE of -93.98%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow-93.98%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Aspire Biopharma Holdings (ASBP) currently reports a ROE of -93.98%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Aspire Biopharma Holdings's ROE history and peer comparisons.
Aspire Biopharma Holdings's ROE of -93.98% is lower than the its sector sector average of 11.64%. That is roughly 907.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Aspire Biopharma Holdings's current -93.98% should be judged against industry norms (sector average: 11.64%) and against ASBP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -93.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Aspire Biopharma Holdings, and consider following ASBP for alerts when major investors trade the stock.
